Izotropic Corporation (IZO)

Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCCJuly 2, 2026 8:00 AM
NewsfileVancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, further to its April 29, 2026 announcement, it has executed the Formal Agreement (the "Formal Agreement") with Izotropic Africa ("IZAF"), together with the Distribution Agreement and Shareholders' Agreement, establishing the definitive commercial, operational, and governance framework for the commercialization of IzoView throughout Africa and the Gulf Cooperation Council ("GCC") (collectively, the "Territory").The Formal Agreement finalizes the ownership of Izotropic Africa, with 51% owned by IZAF shareholders and 49% owned by Izotropic and appoints IZAF as Izotropic's exclusive distributor and commercialization partner throughout the Territory. The increased ownership interest held by Izotropic reflects the significant strategic opportunities developing throughout Morocco and the Territory and the Company's expanded commitments to the long-term development, commercialization, and growth of IZAF.The Formal Agreement has an initial five (5) year term and provides for an initial five (5) year period of distribution exclusivity commencing upon the first commercial installation within the Territory. Distribution exclusivity is maintained throughout the initial exclusivity period by the continued achievement of the established minimum performance requirements. The Formal Agreement will automatically renew for successive one (1) year terms, provided IZAF continues to satisfy the established performance requirements and remains in compliance with the Formal Agreement, while positioning IZAF to become eligible for exclusive commercialization and distribution rights in additional territories and for future products and technologies that may become available under the Formal Agreement.Under the terms of the Formal Agreement, IZAF will be responsible for sales, marketing, customer development, government and Ministry of Health engagement, regulatory support, installation, technical support, service, maintenance, and ongoing customer operations. The Agreement initially covers the commercialization of IzoView together with associated software, accessories, replacement components, related services, and future products and technologies. Izotropic Corporation retains responsibility for manufacturing, product development, engineering, scientific, technical and clinical support, regulatory oversight, software management, quality systems, and lifecycle management, while continuing to retain ownership and control of its intellectual property, regulatory assets, software, trademarks, future technologies, product improvements, and other proprietary rights associated with the IzoView platform.The Shareholders' Agreement establishes the ownership and governance arrangements applicable to IZAF. Certain provisions have been intentionally reserved for future determination and will be completed by an amendment following the conclusion of certain material developments currently underway that are expected to influence those provisions. The parties do not expect this to impact the ongoing governance or business activities of IZAF. With the Formal Agreement now in place, IZAF will proceed with the expansion of regulatory submissions across key jurisdictions in the Territory, deployment of initial clinical and demonstration systems, acceleration of hospital onboarding and pilot site activation, formalization of government and institutional partnerships, advancement of manufacturing and regional assembly feasibility studies, and scaling of commercial pipelines across priority markets.Mr. Mohammed Sair, General Manager, IZAF Comments:"We are proud to reach this strategic milestone with Izotropic Corporation. This Formal Agreement constitutes a solid foundation for the development of Izotropic's activities in Morocco, Africa, and the Gulf Cooperation Council countries.In Morocco, where we are currently hosting Izotropic management, we are actively pursuing the necessary regulatory procedures to prepare for the introduction of Izotropic's technologies to the market. In this context, we have initiated the process of preparing a research dossier in collaboration with the AMMPS in Morocco. In parallel, we have engaged leading healthcare institutions for future clinical evaluations, while strengthening relationships with major hospital groups across Africa and the GCC.We are also advancing discussions with industrial partners, strategic investors, and funding institutions regarding the establishment of a high-technology manufacturing facility in Morocco. This initiative is aligned with a long-term vision to position Morocco as a regional hub for production, distribution, and technical support for Izotropic's advanced breast imaging solutions.We are confident that this collaboration will improve access to next-generation medical technologies and strengthen healthcare capacity across the region." About Izotropic:More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Contacts:Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.comGeneral and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.comIzotropic Africa
Email: IZAF@izocorp.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/303637 Original: Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC

Izotropic Africa Launches Operations in CasablancaApril 29, 2026 8:00 AM
NewsfileVancouver, British Columbia and Casablanca, Morocco--(Newsfile Corp. - April 29, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces the official launch of Izotropic Africa in Casablanca, Morocco, and the appointment of Mr. Mohammed Sair as General Manager. Advancing Regional Operations and Market Deployment Across Africa and the GCCIzotropic Africa will operate across 38 African countries and the GCC countries (Saudi Arabia, UAE, Qatar, Kuwait, Oman, and Bahrain) and is supported by an established and active network of government stakeholders and Ministries of Health, major hospital groups and diagnostic networks, clinical research institutions, and industrial and financial partners. Casablanca has been selected as the regional headquarters due to its logistics infrastructure, industrial capacity, and connectivity across Africa, Europe, and the Middle East. From this base, Izotropic Africa is coordinating strategic management and regional coordination, regulatory and clinical documentation across jurisdictions, training, education, and support programs, software deployment and platform updates, and coordination of clinical, institutional, and partner engagement. Izotropic Africa is advancing localized manufacturing and assembly opportunities in Morocco, strategic industrial partnerships to support regional scaling, and engagement with regional investment funds focused on healthcare infrastructure. Izotropic Africa intends to pursue CE Mark approval for IzoView in Europe, leveraging Morocco as a strategic operational base with preliminary discussions already initiated with a Notified Body to support the EU approval process, alongside regulatory engagement across African and GCC markets.12-Month Execution PlanDiscussions are already underway with several major hospital groups and healthcare organizations. A lease has been executed for Izotropic Africa's headquarters. Over the next 12 months, Izotropic Africa will focus on introducing IzoView to established medical networks across target countries, conducting clinical and technical presentations with Izotropic teams, engaging leading hospitals to secure pilot and early adopter sites, advancing commercial initiatives and structured sales programs, and progressing regulatory pathways across multiple jurisdictions.With Izotropic Africa now operational, the Company is advancing formalization of regional agreements, deployment of initial clinical systems, expansion of institutional and government partnerships, acceleration of regulatory approvals, and development of industrial and funding partnerships.Upon regulatory approval, Izotropic Africa projects 40 IzoView sales in year 1, growing to 300 cumulative sales by year 5. Letter Agreement AmendmentFurther to the Company's February 18th press release, Izotropic and Izotropic Africa have entered into a Definitive Letter Agreement with Amendments and are extending the deadline to finalize the Formal Agreement to June 30, 2026. The extension reflects ongoing engagements and scheduled meetings with hospital groups, healthcare organizations, and funding entities in connection with the development of Izotropic Africa's regional operations and provides additional time to finalize certain material components of the Formal Agreement, specifically those related to the Shareholder and Master Distributor arrangements. Izotropic Africa's General Manager Comments"Since the initial announcement of Izotropic's expansion, we have established a strong operational foundation and initiated advanced discussions with governments, healthcare institutions, and strategic partners across Africa and the GCC.This is not a conventional market entry, but the development of a long-term healthcare infrastructure platform designed to address significant unmet needs across the region. There is strong alignment with governments and healthcare institutions seeking to expand access to advanced diagnostics, and we are working alongside partners to advance these initiatives.We believe this represents a critical inflection point, where coordinated deployment of advanced imaging technologies has the potential to redefine standards of care." -Mr. Mohammed SairAbout Mr. Mohammed Sair:
Mr. Mohammed Sair is a senior executive with over 25 years of international experience across Africa, the Middle East, and Europe, specializing in healthcare infrastructure, medical device distribution, and regulated health-sector operations. He has led the establishment and expansion of regional healthcare platforms, with a proven track record in market entry strategy, regulatory navigation, and large-scale project execution. Mr. Sair previously served as Founder and CEO of a Casablanca-based medical device and hospital engineering company, where he oversaw major healthcare deployments, strategic partnerships, and compliance frameworks. His experience spans healthcare logistics, industrial operations, and infrastructure development, with deep expertise in building partnerships with government institutions, hospital networks, and private-sector stakeholders across multiple African markets. Mr. Sair holds a Mechanical Engineering degree and a Marine Chief Engineer diploma, and is fluent in Arabic and French, with professional proficiency in English. About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Contacts:Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast@izocorp.comGeneral and Corporate Inquiries
Telephone: 1-604-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.comIzotropic Africa
Email: IZAF@izocorp.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/294794
Original: Izotropic Africa Launches Operations in Casablanca

Izotropic Announces Debt SettlementApril 21, 2026 2:09 PM
NewsfileVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - April 21, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a debt settlement agreement (the "Agreement") with a lender (the "Lender") to settle a portion of the principal balance pursuant to a promissory note originally issued by the Company.The Company previously entered into a promissory note dated April 1, 2022, with the Lender in the principal amount of $2,000,000 (the "Promissory Note"). Pursuant to the Agreement, the Company will settle $100,000 of the principal balance through the issuance of 500,000 units (each, a "Unit") at a deemed price of $0.20 per Unit, in full settlement of the portion of the principal balance. Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Share (each, a "Warrant Share") at a price of $0.20 per Warrant Share for a period of three (3) years from the date of issuance.All securities to be issued in connection with the Interest Settlement will be subject to a statutory hold period of four (4) months and one (1) day, in accordance with applicable securities laws.Completion of the Interest Settlement remains subject to the approval of the Canadian Securities Exchange.About Izotropic:More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Contacts:Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast @Olive-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/293628
Original: Izotropic Announces Debt Settlement

Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & HealthFebruary 25, 2026 8:00 AM
NewsfileVancouver, British Columbia, and Sacramento, California--(Newsfile Corp. - February 25, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that, further to its February 18th announcement regarding the formation "Izotropic Africa" under a Letter Agreement, the proposed Casablanca-based entity has entered into partnership discussions with the Mohammed VI Foundation for Science & Health ("FM6SS"). The FM6SS operates as a public utility institution under the patronage of King Mohammed VI, supporting healthcare reform, research advancement, innovation, and institutional partnerships within Morocco. Izotropic Africa is being developed to pursue the licensing, marketing, and distribution of the Company's proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. Under the Letter Agreement, Izotropic will hold a 40% fully diluted interest in Izotropic Africa, subject to conditions, and the parties have agreed to negotiate in good faith to finalize and enter into a Formal Agreement by April 30, 2026.The partnership discussions between Izotropic Africa and the FM6SS are focused on clinical research, regulatory advancement, and manufacturing and assembly opportunities in Morocco for the Company's proprietary medical device, the IzoView Breast CT Imaging System. As part of these discussions, an IzoView device valued at USD $500K would be placed at a leading hospital in Morocco at no cost as a clinical research site to support local clinical evaluation and regulatory approvals. The discussions also include the evaluation of opportunities for localized manufacturing and assembly initiatives in Morocco, with the kingdom's geographic position at the intersection of Europe, Africa, and the Middle East providing access to regional markets with established logistics channels.As part of its broader manufacturing mission, the Kingdom of Morocco is advancing a coordinated national strategy to strengthen domestic medical device manufacturing, expand access to advanced healthcare technologies, and build long-term research and development capacity. In early February, during Morocco's second annual Medical Device Day, a 2026-2030 national framework agreement was signed by the Ministry of Health and Social Protection, the Ministry of Industry and Trade, the Moroccan Agency for Medicines and Health Products, the General Confederation of Moroccan Enterprises, and the Federation of the Medical Device Industry. The agreement outlines national priorities to strengthen domestic production capacity, reinforce supply-chain resilience, promote "Made in Morocco" manufacturing, support industrial investment, and align workforce development with sector growth. Morocco operates 15 ports, including Tangier Med, the largest port in Africa and the Mediterranean, and offers more than 150 sector-specific industrial zones that enable companies to establish and scale production efficiently. Export-oriented industrial acceleration zones provide defined exemptions from value-added tax, business tax for 15 years, and corporate tax for five years.The formalization of this national framework reinforces the strategic relevance of Izotropic Africa's discussions with FM6SS and supports the planned role of Izotropic Africa in advancing clinical research, regulatory progression, and localized manufacturing initiatives for IzoView Breast CT.About Izotropic Africa:
Izotropic has entered into a Letter Agreement with a Business Group ("BG") to incorporate Izotropic Africa in Casablanca, Morocco, to establish operations, and pursue the licensing, marketing, and distribution of the Company's proprietary IzoView Breast CT Imaging System and certain follow-on products throughout Africa and the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates) while also evaluating manufacturing and/or assembly of in Morocco. BG will hold a 60% fully diluted interest in the entity, and Izotropic will hold a 40% fully diluted interest, subject to final corporate, tax, regulatory, repatriation structuring, and legal advice acceptable to both parties. The parties have agreed to negotiate in good faith to finalize and enter into a Formal Agreement by April 30, 2026. About Izotropic:
More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.Forward-Looking Statements:
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Contacts:
Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast @Olive-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/285211
Original: Izotropic's "Izotropic Africa" Enters Partnership Discussions with the Mohammed VI Foundation for Science & Health

Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCCFebruary 18, 2026 8:00 AM
NewsfileVancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 18, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that it has entered into a Letter Agreement (the "Agreement") with a business group ("BG") to establish an entity named Izotropic Africa (the "Entity") based in Casablanca, Morocco. The Entity is intended to license, market, distribute, and evaluate manufacturing and/or assembly of IzoView Breast CT and certain follow-on products in all of Africa and the Gulf Cooperation Council ("GCC"): Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (the "Business Purpose").The establishment of Izotropic Africa is intended to expand the Company's commercial footprint into regions where access to advanced breast imaging remains limited, positioning Morocco as a strategic gateway for deployment, regulatory engagement, and potential future regional manufacturing initiatives. Breast cancer is the most prevalent cancer among African women, with over 200,000 annual cases and mortality rates exceeding 50% due to delayed diagnoses and limited access to advanced care. The addressable market for advanced imaging and oncology devices in Africa is projected to exceed USD $500 million by 2030, reflecting significant unmet demand and long-term regional growth potential. Under the terms of the Agreement, the parties will incorporate the Entity and establish a local office for operations, with BG holding a 60% fully diluted interest and Izotropic holding a 40% fully diluted interest, subject to final corporate, tax, regulatory, repatriation structuring and legal advice acceptable to both Parties, and have agreed to negotiate in good faith to finalize and enter into a Formal Agreement (the "Formal Agreement") by April 30, 2026, which will define the detailed material terms and commitments contemplated in the Agreement. The Agreement will terminate upon execution of the Formal Agreement or if the Parties fail to enter into the Formal Agreement by that date. Under the Agreement, BG has committed to developing and executing an annual business plan focused on the sales, marketing, and distribution of IzoView and any follow-on products in Africa and the GCC. BG has further committed to securing a major hospital site in Morocco in Q1, 2026 for installation of an IzoView Breast CT Imaging System to serve as a research data collection and clinical study and approval location forming the foundation for regulatory engagement and market entry within the region, initiating approval processes with Government health ministries in the designated territories, and assessing the feasibility of establishing manufacturing and/or assembly capabilities in Morocco to serve Africa and the GCC.Izotropic is committed to supporting the establishment of the Entity through technical, clinical, and operational participation, including the intention to build, ship, and install the first IzoView Breast CT Imaging system for research and clinical approval processes in Morocco in partnership with the aforementioned designated hospital, subject to execution of the Formal Agreement and securing the required financing. The parties have agreed upon an estimated first-year start-up budget, pursuant to which Izotropic's 40% share is estimated at USD $120K. Izotropic has agreed to advance 25% (USD $30K) for the first three-month period against its portion of those estimated costs. All financial contributions and operational commitments of Izotropic beyond the initial capital advance remain expressly subject to execution of the Formal Agreement and securing of financing. About Izotropic:More information about Izotropic Corporation can be found on its corporate website at izocorp.com and by reviewing its profile on SEDAR+ at sedarplus.ca.Forward-Looking Statements:This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections, and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks, including those related to capital requirements and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants shall be liable for any action and the results of any action taken by any person based on the information contained herein, including, without limitation, the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind. All images are for illustrative purposes only. IzoView has not yet been approved or cleared for sale.Contacts:Robert Thast, Interim Chief Executive Officer
Telephone: 1-604-220-5031 or 1-833-IZOCORP ext. 1
Email: bthast @Olive-825-4778 or 1-833-IZOCORP ext. 3
Email: info@izocorp.comTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/284237
Original: Izotropic Signs Letter Agreement for Regional Operations in Africa & the GCC

I communicate with you dummy because you might say something that clicks for me!! So far nothing!! Lol 😂

MOVE ON LOSER...I JUST MADE YOU LOOK LIKE THE IDIOT U R!1

Who is the person who believes in charting?? I might check them before I enter!! After that I know what I want it to look like.....Up!!

ROTFLMAO SHOW ME THE CHARTS

Baba, sinc, amlh, bcap, jamn!! Heavy in all!! Just assume 3K or better!!

POST ME SOME CHARTS OF YOUR PLAYS

Unless you have an infinite amount of money your Strategy is terrible!! It also says you have no confidence in your Strategy!! Pick 4 or 5 go heavy and make Bank!! Now if you're just playing darts 🎯 continue on!!

HERES ANOTHER CAN BIO READY TO FLY...OUCH////////////////https://stockcharts.com/sc3/ui/?s=ABCL

You mean like the last one predicted that's still sitting collecting dust?? Lol 😂 I'm not even going to go through the trouble of disturbing my watch list!!

DUMMY...STICK TO YOUR BAGS...15C TO 46C...WATCH AND LEARN...HERES MY NEXT CANADIAN PLAY...CTRL.V 1000 SHARES AT 53C THIS MORNING
https://stockcharts.com/sc3/ui/?s=CTRL.V#google_vignette

You big dummy it already moved!! How much did you invest?? That what's important!! Many factors go into a trade!!

IZOZF MONSTER

IZO.CA THE BEAST OF CANADIAN BEASTS...READY TO BEAST INTO BEASTVILLE TO 44C

IZO.CA monster is getting mad, she’s raging

IZO.CA monster

IZO.CA monster

IZO.CA monster

IZOZF/IZO.CA HOTTEST CANADAN PLAY RIGHT NOW

IZOZF/IZO.CA READY TO FLY

IZOZF/IZO.CSE HOT CANADIAN MEDICAL PLAY...BREAK THROUGH BREAST CANCER TOMOGRAPHY PLAY WITH FDA AROUND THE CORNER

Ya agreed. I have been slowly adding. will see what happens!

Started buying a few weeks ago, stock doing well, surprised there is not more attention being paid to this one.

strong buy check out $izozf!! $izozf gets a mention in article! Could explode. $lnth $vrex Bullish https://www.prnewswire.com/news-releases/exciting-diagnostic-innovations-alter-the-healthcare-landscape-301060563.html